Varlilumab

CAS No. 1393344-72-3

Varlilumab( —— )

Catalog No. M36678 CAS No. 1393344-72-3

Varlilumab (CDX-1127) is a novel human IgG1 anti-CD27 monoclonal antibody with antitumor activity, useful for studying advanced solid tumors.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 945 Get Quote
5MG 2014 Get Quote
10MG 2717 Get Quote
25MG 3892 Get Quote
50MG 5272 Get Quote
100MG 6957 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Varlilumab
  • Note
    Research use only, not for human use.
  • Brief Description
    Varlilumab (CDX-1127) is a novel human IgG1 anti-CD27 monoclonal antibody with antitumor activity, useful for studying advanced solid tumors.
  • Description
    Varlilumab (CDX-1127) is a first-in-class human IgG1 anti-CD27 monoclonal antibody. Varlilumab has an anti-tumor activity.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Apoptosis
  • Target
    TNF
  • Recptor
    TNF
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1393344-72-3
  • Formula Weight
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Stephen M Ansell, et al. Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies. Blood Adv. 2020 May 12;4(9):1917-1926.?
molnova catalog
related products
  • Homovanillyl alcohol

    Homovanillyl alcohol is a biological metabolite of Hydroxytyrosol.?

  • Ragifilimab

    Ragifilimab (INCAGN-1876) is an agonist monoclonal antibody that targets glucocorticoid-induced TNFR-associated protein (GITR) and can be used in the study of advanced or metastatic solid tumors.

  • Armepavine

    Armepavine exerted both in vitro and in vivo antifibrotic effects in rats, with inhibition of NF-κB, JunD and C/EBP? pathways.